Resources
Toolkit for New Buprenorphine Prescribers
Clinical Guides and Algorithms
Screening and Assessment Tools
- The CAGE and CAGE-AID QuestionnairesCAGE questionnaire is a screening test for unhealthy alcohol use and alcohol dependence. The CAGE-AID was adapted to include drugs as well as alcohol
- ASSIST Version 3.0Screening test for unhealthy use of tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens and opioids. It takes about 5-10 minutes to complete.
- The AUDIT (Alcohol Use Disorder Identification Test)Screening test for unhealthy alcohol use.
- DAST-10 (Drug Abuse Screen Test)Screening test that measures degree of consequences related to drug use excluding alcohol use.
- Opioid Risk ToolSelf-report screening tool designed to assess adult primary care patients for risk of developing opioid use disorder if prescribed opioids for chronic pain
- Clinical Opioid Withdrawal Scale
MOC Webinars
In the Clinic
- Benzodiazepines
- Beyond the Waiver: Practical Tips for Buprenorphine Prescribers
- Buprenorphine Management in Patients with Pain
- Drug Screening
- Gabapentinoids
- Introduction to Adolescent Substance Use
- Methamphetamine: New Risks, Current Treatments
- Motivational Interviewing: Affirmations
- Motivational Interviewing and Opioid Use for Prescribers
- Neurobiology of Addiction
- OUD and Pregnancy
- Tobacco Use Disorder
- Integrating Reproductive and Sexual Health Services in OUD Treatment
Policy and/or Research
- Addiction Treatment for Patients with Endocarditis
- Drug Legalization in the U.S.
- Marijuana Related Healthcare Utilization and Legalization
- Substance Use Disorder in Rural Communities
- Telemedicine Delivery of Substance Use Disorder Treatment
- Treatment Gaps for Patients Taking Opioids for Chronic Pain
Chronic Pain Resources
Waiver Training and Support
Hepatitis C Resources
Research Articles
Diversion
- A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World
- Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
- Diversion of Methadone and Buprenorphine from Opioid Substitution Treatment: Patients who Regularly Sell or Share Their Medication
- Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma
- Perceptions and practices addressing diversion among US buprenorphine prescribers
- The relationship between diversion-related attitudes and sharing and selling buprenorphine
Emergency Department
- Cost Effectiveness of Emergency Department-Initiated Treatment for Opioid Dependence
- Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization
- Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence
- Emergency department-based peer support for opioid use disorder: Emergent functions and forms
- Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention
- Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program
- One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose
MAT/MOUD Effectiveness
- Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review)
- Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality
- Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009
- Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids
Pregnancy
- Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?
- Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations
- Simultaneous quantification of buprenorphine, naloxone and phase Iand II metabolites in plasma and breastmilk by liquid chromatography–tandem mass spectrometry
Primary Care
- Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study
- A buprenorphine education and training program for primary care residents: Implementation and evaluation
- Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine
- Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization
- Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers
Stigma
- Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms
- Does Out Choice of Substance-Related Terms Influence Perceptions of Treatment Need? An Empirical Investigation with Two Commonly Used Terms
- Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation
- Caring for Ms. L. — Overcoming My Fear of Treating Opioid Use Disorder
- Stigma as a fundamental hindrance to the United States opioid overdose crisis response
- Next Stage in Burprenorphine Treatment (Addresses misconceptions about MOUD)
- Interpreting Urine Drug Screen (UDS)
Other Substance Use Resources and Websites
Other substance use disorder treatment organizations and resources
- American Society of Addiction Medicine (ASAM)
- Boston Medical Center (BMC) Office Based Addiction Treatment (OBAT)
- Provider Clinical Support System (PCSS)
- American Association for the Treatment of Opioid Dependence, Inc. (AATOD)
- Harm Reduction Approach to Treatment of All Substance Use Disorders
- National Harm Reduction Coalition